EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting

Jens Wiebe iD, Robert A Byrne, Christian Bradaric, Constantin Kuna, Thorsten Kessler, Mathieu Pfleiderer iD, Sebastian Kufner, Erion Xhepa, Petra Hoppmann, Michael Joner, Heribert Schunkert iD, Karl-Ludwig Laugwitz und 2 weitere

Journal of Clinical Medicine · 07.10.2024 · 13 (19) · 5949

DOI: 10.3390/jcm13195949 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.10.2024. Verfasst von Jens Wiebe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstrasse 36, 80636 Munich, Germany. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Heart Centre Munich, Germany, Abbott Medical GmbH, Wetzlar, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The performance of an everolimus-eluting bioresorbable scaffold (BRS) was inferior to an everolimus-eluting metallic drug-eluting stent (DES) with permanent polymer, mainly due the mechanical features of BRS technology. The performance of BRS as compared to metallic DES with bioresorbable polymers remains unstudied.

Methods

This prospective, randomized, multicenter, clinical trial enrolled patients who underwent coronary stenting for de novo coronary lesions. Patients were randomly assigned to bioresorbable polymer everolimus-eluting stents (BP-EES) or everolimus-eluting BRS. The primary endpoint was percentage diameter stenosis (in-device) at 6- to 8-month angiographic surveillance. The main secondary endpoint was the device-oriented composite endpoint (DOCE) of cardiac death/target vessel-myocardial infarction/target lesion revascularization assessed after 12 months and 5 years.

Results

The trial was prematurely terminated after the enrollment of 117 of 230 patients (BP-EES, n = 60; BRS, n = 57) due to safety issues associated with BRS technology. The primary endpoint of in-device diameter stenosis at angiographic surveillance was 12.5 ± 7.7% with BP-EES versus 19.3 ± 16.5% with BRS (p = 0.01). The DOCE occurred in 5.0% in the BP-EES group versus 12.3% of patients in the BRS group (hazard ratio [HR] 2.48, 95% confidence interval [CI] 0.64–9.58, p = 0.19) after 12 months and in 11.7% in the BP-EES group versus 26.4% of patients in the BRS group (HR 2.38, 95% CI 0.97–5.84, p = 0.06) after 5 years.

Conclusions

BP-EES showed superior mid-term angiographic performance compared with BRS. Clinical event rates did not differ significantly between the groups up to 5 years of follow-up. These results should be interpreted with caution in view of the premature discontinuation of the study.

Schlagwörter

Stichwörter der Autor:innen

drug-eluting stentpercutaneous coronary interventionscaffold

Autor:innen und Institutionen

  • Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstrasse 36, 80636 Munich, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, 81377 Munich, Germany.
  • Cardiovascular Research Institute, Mater Private Hospital, D07 WKW8 Dublin, Ireland.
  • School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
  • 1. med. Klinik, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany.

ORCID-Profile: Jens Wiebe, Mathieu Pfleiderer, Heribert Schunkert

Förderung

  • German Heart Centre Munich, Germany
  • Abbott Medical GmbH, Wetzlar, Germany

Zitieren

APA

Wiebe, J., Byrne, R. A., Bradaric, C., Kuna, C., Kessler, T., Pfleiderer, M., Kufner, S., Xhepa, E., Hoppmann, P., Joner, M., Schunkert, H., Laugwitz, K. L., Kastrati, A., & Cassese, S. (2024). A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting. Journal of Clinical Medicine, 13(19), 5949. https://doi.org/10.3390/jcm13195949

Vancouver

Wiebe J, Byrne RA, Bradaric C, Kuna C, Kessler T, Pfleiderer M, et al. A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting. Journal of Clinical Medicine. 2024;13(19):5949. doi:10.3390/jcm13195949

BibTeX
@article{Wiebe2024,
  author = {Wiebe, Jens and Byrne, Robert A and Bradaric, Christian and Kuna, Constantin and Kessler, Thorsten and Pfleiderer, Mathieu and Kufner, Sebastian and Xhepa, Erion and Hoppmann, Petra and Joner, Michael and Schunkert, Heribert and Laugwitz, Karl-Ludwig and Kastrati, Adnan and Cassese, Salvatore},
  title = {A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {19},
  pages = {5949},
  doi = {10.3390/jcm13195949}
}
Kostenlos starten →